XML 15 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Mar. 06, 2025
Jun. 30, 2024
Document Document And Entity Information [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Entity File Number 001-39527    
Entity Interactive Data Current Yes    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Title of 12(b) Security Common Stock, par value $0.0001 per share    
Security Exchange Name NASDAQ    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Trading Symbol PRLD    
Entity Registrant Name PRELUDE THERAPEUTICS INC    
Entity Central Index Key 0001678660    
Entity Current Reporting Status Yes    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Shell Company false    
Entity Ex Transition Period false    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 81-1384762    
Entity Address, Address Line One 175 Innovation Boulevard    
Entity Address, City or Town Wilmington    
Entity Address, State or Province DE    
Entity Address, Postal Zip Code 19805    
City Area Code 302    
Local Phone Number 467-1280    
Entity Common Stock, Shares Outstanding   55,154,634  
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Public Float     $ 66.1
Auditor Firm ID 42    
Auditor Name Ernst & Young LLP    
Auditor Location Philadelphia, Pennsylvania    
Documents Incorporated by Reference

Portions of the Registrant’s Definitive Proxy Statement (“Proxy Statement”) relating to the 2025 Annual Meeting of Stockholders will be filed with the Commission within 120 days after the end of the Registrant’s 2024 fiscal year pursuant to Regulation 14A and is incorporated by reference into Part III of this Report. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form 10-K.

    
Auditor Opinion [Text Block]

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Prelude Therapeutics Incorporated (the Company) as of December 31, 2024 and 2023, the related statements of operations and comprehensive loss, changes in stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.